Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Beta Bionics, Inc.NASDAQ: BBNX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables dips below year-ago levels

Q1 FY2026 accounts receivables of $1.37M fell 53.4% year over year, behind the +143.5% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 5.1% of revenue in FY2025, down 6.5 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -53.4% toward the trailing-twelve-month pace of +143.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.37M+124.5% QoQ
Last fiscal yearDec 2025
-$5.16M-32.2% YoY
LTMMar 2026
-$6.73M+143.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-53.4%——
1 year-32.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(5.16M) USD
Year-over-year change
+32.2%

Accounts Receivables vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +143.5% is the 2nd highest of 5, against a peer median of +89.5%.
  • Accounts receivables amounts to 6.1% of revenue for BBNX, versus a peer median of 2.9%.
BBNX Competitors
Accounts Receivables for BBNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$681M USD—+97.3%21.1%
PODDInsulet CorporationLTM Jun 2026$107.5M USD+57.9%+39.4%3.5%
DXCMDexCom, Inc.LTM Jun 2026$84.1M USD+121.2%+0.3%1.7%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$23.29M USD-43.8%+93.6%2.3%
MNKDMannKind CorporationLTM Mar 2026$22.62M USD+351.7%-26.1%6.3%
BBNXBeta Bionics, Inc.LTM Mar 2026$6.73M USD+143.5%—6.1%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$0 USD———
Peer median (excluding BBNX) —+89.5%+39.4%2.9%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Depreciation & Amortization2.09M2.09M2.28M2.88M
Deferred Income Tax0000
Stock-Based Compensation6.1M5.66M6.38M16.38M
Change in Working Capital(2.79M)(6.36M)(12.15M)(8.99M)
Accounts Receivables0(4.49M)(7.62M)(5.16M)
Inventory0(1.19M)(11.44M)(9.88M)
Accounts Payables(77K)716K1.52M2.1M
Other Working Capital(2.71M)(682K)5.39M3.95M
Other Non-Cash Items(854K)10.27M9.96M12.01M
Operating Cash Flow(60.21M)(32.45M)(48.27M)(50.93M)
Capital Expenditures(772K)(402K)(3.4M)(5.3M)
Acquisitions (Net)0000
Purchases of Investments0(69.3M)(72.13M)(327.51M)
Sales of Investments0072M170M
Other Investing Activities3K(69.29M)50K0
Investing Cash Flow(769K)(69.69M)(3.48M)(162.81M)
Debt Repayment0000
Common Stock Issued389K29K55.62M214.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities389K101.03M00
Financing Cash Flow56.78M101.03M55.62M214.87M
Effect of Forex Changes0000
Net Change in Cash(4.2M)(1.11M)3.87M1.14M
Free Cash Flow(60.98M)(32.85M)(51.67M)(56.22M)

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.